Hereditary angioedema (HAE) is a genetic disorder that causes episodes of extreme swelling (angioedema), commonly in the face, hands, feet, digestive tract, or upper airways. Symptoms may begin ...

Discover a study in which the analysis demonstrated significant reductions in HAE attacks among adolescent patients.

The company is on track to complete enrollment in the global Phase 3 HAELO study for hereditary angioedema (HAE) by the third quarter of 2025 and has dosed the first patient in the Phase 3 ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Hereditary angioedema is characterized by unpredictable swelling involving the face, oropharynx, extremities, or abdomen, without hives or pruritus. Laryngeal attacks carry a risk of asphyxiation, ...

KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.